Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Liabilities: 2020-2025

Historic Total Liabilities for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $371.1 million.

  • Xeris Biopharma Holdings' Total Liabilities rose 6.19% to $371.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $371.1 million, marking a year-over-year increase of 6.19%. This contributed to the annual value of $352.7 million for FY2024, which is 7.07% up from last year.
  • Xeris Biopharma Holdings' Total Liabilities amounted to $371.1 million in Q3 2025, which was up 4.82% from $354.0 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Total Liabilities' 5-year high stood at $371.1 million during Q3 2025, with a 5-year trough of $133.7 million in Q3 2021.
  • Its 3-year average for Total Liabilities is $339.5 million, with a median of $349.4 million in 2024.
  • Data for Xeris Biopharma Holdings' Total Liabilities shows a peak YoY surged of 1,032.76% (in 2021) over the last 5 years.
  • Xeris Biopharma Holdings' Total Liabilities (Quarterly) stood at $209.1 million in 2021, then surged by 43.13% to $299.3 million in 2022, then climbed by 10.04% to $329.4 million in 2023, then grew by 7.07% to $352.7 million in 2024, then climbed by 6.19% to $371.1 million in 2025.
  • Its Total Liabilities stands at $371.1 million for Q3 2025, versus $354.0 million for Q2 2025 and $350.6 million for Q1 2025.